晚期人类免疫缺陷病毒病患者中利福平及其他抗结核药物的生物利用度降低。
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
作者信息
Gurumurthy Prema, Ramachandran Geetha, Hemanth Kumar A K, Rajasekaran S, Padmapriyadarsini C, Swaminathan Soumya, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P
机构信息
HIV-AIDS Division, Tuberculosis Research Centre (Indian Council of Medical Research), Mayor V.R. Ramanathan Rd., Chetput, Chennai 600 031, India.
出版信息
Antimicrob Agents Chemother. 2004 Nov;48(11):4473-5. doi: 10.1128/AAC.48.11.4473-4475.2004.
Abstract
We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine. Peak concentration and exposure were reduced for rifampin, and rapid acetylators of isoniazid had lower drug levels. HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs.
摘要
我们通过测量血液中异烟肼和利福平的浓度以及尿液中吡嗪酰胺和乙胺丁醇的浓度，评估了人类免疫缺陷病毒（HIV）疾病对抗结核药物药代动力学的影响。利福平的峰值浓度和暴露量降低，而异烟肼的快速乙酰化者药物水平较低。患有腹泻和隐孢子虫感染的HIV患者及HIV合并结核病患者对抗结核药物的生物利用度降低。
相似文献
1
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Antimicrob Agents Chemother. 2004 Nov;48(11):4473-5. doi: 10.1128/AAC.48.11.4473-4475.2004.
2
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7. doi: 10.1128/AAC.50.4.1170-1177.2006.
3
Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.
Clin Infect Dis. 2004 Jan 15;38(2):280-3. doi: 10.1086/380795. Epub 2003 Dec 19.
4
Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
Antimicrob Agents Chemother. 2015 Oct;59(10):6175-80. doi: 10.1128/AAC.01193-15. Epub 2015 Jul 27.
5
Does AIDS impair the absorption of antituberculosis agents?
Int J Tuberc Lung Dis. 1998 Aug;2(8):670-5.
6
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
Clin Infect Dis. 2005 Aug 15;41(4):461-9. doi: 10.1086/431984. Epub 2005 Jul 8.
7
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Int J Tuberc Lung Dis. 2016 May;20(5):666-72. doi: 10.5588/ijtld.15.0288.
8
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
Ann Intern Med. 1997 Aug 15;127(4):289-93. doi: 10.7326/0003-4819-127-4-199708150-00006.
9
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040.
10
The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1580-4. doi: 10.1164/ajrccm.159.5.9810034.
引用本文的文献
1
Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects.
Front Drug Deliv. 2024 Jan 8;3:1295815. doi: 10.3389/fddev.2023.1295815. eCollection 2023.
2
A competing risk analysis of predictors of time to lost to follow-up among adults with TB/HIV coinfection in Bahir Dar.
Sci Rep. 2025 Aug 19;15(1):30362. doi: 10.1038/s41598-025-15985-8.
3
Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0120024. doi: 10.1128/aac.01200-24. Epub 2024 Dec 23.
4
Association between HIV and acquisition of rifamycin resistance with first-line TB treatment: a systematic review and meta-analysis.
BMC Infect Dis. 2024 Jul 1;24(1):657. doi: 10.1186/s12879-024-09514-7.
5
Pharmacomicrobiomics and Drug-Infection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy.
Int J Mol Sci. 2023 Dec 4;24(23):17100. doi: 10.3390/ijms242317100.
6
Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance.
Front Pharmacol. 2023 May 26;14:1116226. doi: 10.3389/fphar.2023.1116226. eCollection 2023.
7
Effect of Rifabutin in Dolutegravir Dosing: A Case Series.
J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221111077. doi: 10.1177/23259582221111077.
8
Determinants of unsuccessful tuberculosis treatment outcome in Northern Red Sea region, Eritrea.
PLoS One. 2022 Aug 15;17(8):e0273069. doi: 10.1371/journal.pone.0273069. eCollection 2022.
9
Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.
J Clin Pharmacol. 2022 Oct;62(10):1206-1214. doi: 10.1002/jcph.2068. Epub 2022 Jun 13.
10
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study.
Lancet Microbe. 2021 Nov;2(11):e584-e593. doi: 10.1016/S2666-5247(21)00144-0.
本文引用的文献
1
Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid.
Indian J Exp Biol. 2004 Jan;42(1):68-73.
2
Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.
Clin Infect Dis. 2004 Jan 15;38(2):280-3. doi: 10.1086/380795. Epub 2003 Dec 19.
3
Does AIDS impair the absorption of antituberculosis agents?
Int J Tuberc Lung Dis. 1998 Aug;2(8):670-5.
4
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
Ann Intern Med. 1997 Aug 15;127(4):289-93. doi: 10.7326/0003-4819-127-4-199708150-00006.
5
Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.
Clin Infect Dis. 1997 Jul;25(1):104-11. doi: 10.1086/514513.
6
Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary tuberculosis.
BMJ. 1996 Dec 14;313(7071):1543-5. doi: 10.1136/bmj.313.7071.1543.
7
Low antituberculosis drug concentrations in patients with AIDS.
Ann Pharmacother. 1996 Sep;30(9):919-25. doi: 10.1177/106002809603000901.
8
Malabsorption of antimycobacterial medications.
N Engl J Med. 1993 Oct 7;329(15):1122-3. doi: 10.1056/NEJM199310073291513.
9
Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.
J Infect Dis. 1993 Dec;168(6):1559-62. doi: 10.1093/infdis/168.6.1559.
10
Drug malabsorption and resistant tuberculosis in HIV-infected patients.
N Engl J Med. 1995 Feb 2;332(5):336-7. doi: 10.1056/NEJM199502023320518.
Zotero 插件